A Research Guide for
ITP

• All recent CBC results. If you have been getting blood tests with your primary care doctor, bring printed or digital copies. The trend in your platelet count over time is more informative than any single value. If possible, bring results going back 6–12 months.
• A complete medication list. Include prescription medications, over-the-counter medications, vitamins, supplements, and herbal products. Some common products reduce platelet function (aspirin, NSAIDs like ibuprofen or naproxen, omega-3 at high doses, vitamin E at high doses, fish oil, garlic supplements) and are important for your hematologist to know about.
• Your medical history summary. Recent illnesses (especially viral infections in the weeks before ITP was discovered), prior blood test results showing normal counts, surgeries, significant medical conditions, and family history of blood disorders or autoimmune diseases.
• A written list of your questions and concerns. You will have limited time. Prioritize your three most important questions and write them down so you don't forget under pressure.
• Your insurance card and prior authorization paperwork if you have already received a prior authorization request for a specific test or treatment.

At your first appointment, your hematologist is trying to answer several questions: Is this truly ITP, or could it be something else? How severe is the ITP? Does it need treatment right now, or can we watch it first? Here is the typical flow:

1. History taking (15–20 minutes). Your hematologist will ask about how the low platelets were discovered, any bleeding symptoms you have had, current medications, recent illnesses, family history of blood or autoimmune conditions, and your overall health. Be thorough and honest — the diagnosis is built on this history.
2. Physical examination. Your doctor will examine you for signs of bleeding (petechiae, purpura, bruises), lymph node enlargement (suggests lymphoma), spleen size (splenomegaly suggests secondary causes), and general health. The exam is usually brief but important.
3. Repeat CBC with peripheral blood smear. You will almost certainly have blood drawn. The peripheral smear (examination of your blood under a microscope) is a critical test — it allows the hematologist to confirm the low platelet count, rule out clumping (pseudothrombocytopenia, which is not a true problem), and look for other cell abnormalities that would suggest a different diagnosis. This is almost always done at the first visit even if you have recent results.
4. Additional tests. Depending on your presentation, your hematologist may also order: H. pylori testing (breath test, stool antigen, or serology), thyroid function tests, hepatitis C serology, HIV serology, ANA and other autoimmune markers, direct antiglobulin test (DAT/Coombs), and a complete metabolic panel. These are looking for secondary causes of ITP. They are not always necessary in a classic presentation of a young woman with isolated thrombocytopenia and no other symptoms, but they are important when the presentation is atypical or when initial treatment does not work.
5. Treatment discussion and plan. At the end of the appointment, your hematologist will explain their interpretation and propose a plan. This might be "your count is at a safe level and we're going to watch without treatment," or "your count is below a safe threshold and we're going to start prednisone today," or "we need a few more tests before deciding." Ask the hematologist to explain the plan in plain language and what triggers would change it.

Primary care and emergency care: Often the first to recognize thrombocytopenia on a blood count. Their role is to order initial testing, rule out emergencies, and refer to hematology. They should not be managing ITP long-term without hematology input.

Hematologists: The specialists who diagnose and manage ITP. For straightforward ITP that responds to first-line treatment, a general hematologist is appropriate. For ITP that is refractory to multiple treatments, or for complex situations (pregnancy, surgery, rare complications), referral to an academic medical center with specific ITP expertise is valuable.

When to ask for a second opinion:

• If your ITP has not responded to 2 or more different treatments and your doctor doesn't have a clear next-step plan
• Before agreeing to splenectomy — a second opinion from another hematologist ensures all non-surgical options have been adequately tried
• If you are pregnant or planning pregnancy and your current hematologist has limited experience with ITP in pregnancy
• If your diagnosis is uncertain (some other platelet conditions can look like ITP)
• If you are being recommended a clinical trial and want to understand whether it's appropriate for your situation

ITP centers of excellence: Several U.S. academic medical centers have dedicated ITP programs with hematologists who focus primarily or substantially on ITP and autoimmune blood disorders. At these centers, you may have access to clinical trials, multidisciplinary care (psychologist, social worker, pharmacist specializing in ITP), and protocols for complex situations. The Platelet Disorder Support Association (pdsa.org) maintains a provider directory of ITP specialists.

At each visit, your hematologist will typically:

• Review your most recent platelet count and compare to prior counts
• Ask about bleeding symptoms since the last visit (new bruising, nosebleeds, gum bleeding, menstrual changes, headaches)
• Review any changes to medications (including over-the-counter drugs and supplements)
• Assess your treatment side effects
• Discuss any upcoming procedures, surgery, or travel
• Adjust treatment if needed

How often to be seen: In newly diagnosed or unstable ITP: sometimes as often as weekly until counts stabilize. In stable chronic ITP on effective treatment: typically every 1–3 months with CBC checks in between as needed. In stable ITP not requiring treatment: every 3–6 months is often appropriate.

Between appointments: Call or message your hematologist if you have:

• Any significant new bleeding (see emergency guide above)
• A planned procedure or surgery (do not schedule procedures without notifying your hematologist first)
• A new medication prescribed by another provider (always check if it affects platelet function)
• A significant infection, especially if you are immunosuppressed
• Significant travel planned (they can advise and provide documentation)

At diagnosis:

• Is my ITP primary (no known cause) or secondary? What testing do I need?
• Should I be tested for H. pylori? Lupus? Thyroid disease? HIV? Hepatitis C?
• What is my platelet count now, and at what count do we start treatment?
• What symptoms should make me call you between appointments?
• Are there any medications or supplements I need to avoid?
• Do I need to restrict any activities right now?

When starting steroid treatment:

• How long will I be on steroids? What does the taper look like?
• Do I need calcium, vitamin D, and a stomach protector (proton pump inhibitor)?
• Should I monitor my blood sugar? How often?
• What side effects should prompt me to contact you?
• What is the plan if my count drops again when we taper?

When considering second-line treatment:

• Which second-line treatment do you recommend for me specifically, and why?
• What is the expected response rate and timeframe to response?
• How does this treatment work differently from what I've already tried?
• What monitoring will I need?
• What does this treatment cost, and what patient assistance is available?
• Are there clinical trials I should know about?

Before splenectomy:

• Have all non-surgical options been tried?
• What vaccinations do I need before surgery, and how much in advance?
• Will this be laparoscopic or open?
• What is the expected recovery time?
• What is the plan if splenectomy doesn't produce a response?
• Will I need long-term penicillin prophylaxis after surgery?

Platelets are tiny cell fragments in the blood whose main job is to form the initial plug at a site of injury to stop bleeding. The normal platelet count in adults is 150,000 to 400,000 platelets per microliter of blood (written as 150–400 ×10³/μL in lab reports). In ITP, the immune system destroys platelets faster than the bone marrow can make them, so the count falls.

ITP is typically defined as a platelet count below 100 ×10³/μL, but many people diagnosed with ITP have counts between 50 and 100 — a range where serious bleeding is uncommon in the absence of injury or surgery. The decision to treat in ITP is based far more on symptoms and lifestyle than on the number alone.

General thresholds doctors use (these are guides, not absolute rules):

• 100–150 ×10³/μL: Below normal but rarely causing symptoms. Usually observed without treatment unless surgery is planned.
• 50–100 ×10³/μL: Mild ITP. Most people can live normally. Activity restrictions are minimal. Treatment is often deferred unless there is bleeding or a procedure planned.
• 30–50 ×10³/μL: Moderate ITP. Easy bruising is common. Some lifestyle modifications may be recommended. Treatment decision is individualized — active people or those on blood thinners may be treated; sedentary older adults may be observed.
• 10–30 ×10³/μL: Severe ITP. Risk of spontaneous bleeding (from the skin, gums, or nosebleeds) increases. Most doctors recommend treatment in this range, especially for active individuals.
• Below 10 ×10³/μL: Very severe ITP. Risk of spontaneous serious bleeding is real. Treatment is nearly always recommended. This is the range where platelet transfusion in combination with other medications may be used in emergencies.

One of the most anxiety-provoking aspects of ITP is that platelet counts fluctuate — sometimes dramatically — from week to week or even day to day. Understanding why this happens reduces unnecessary alarm:

• Infections temporarily lower counts. Any infection (viral or bacterial) can cause a temporary dip in platelets because the immune system is activated and producing more antibodies. A count of 15 during a cold may go back to 40 after recovery without any change in treatment.
• Stress and poor sleep can affect the immune response and transiently alter platelet counts.
• Lab variation is real. A 10–20% variation between the same laboratory draw on the same day is within normal analytical range. A count of 28 one week and 35 the next is not necessarily a meaningful change.
• Menstrual cycles in women with ITP can be associated with count fluctuations around the menstrual period.
• Seasonal variation is noted by many people with chronic ITP — spring and fall often bring worse counts, possibly related to higher infection rates and immune activation.

What this means practically: if your count drops from your usual 45 to 22 but you feel well and have no new symptoms, ask your doctor whether observation for 1–2 weeks is appropriate before changing treatment. A single lower count during an illness is different from a persistent new low.

Different activities and procedures have different safe platelet count thresholds. Knowing these helps you understand why your doctor may want a higher count before certain procedures:

• Normal daily activity (including gentle exercise): Safe above 10–20 ×10³/μL in most people
• Minor dental work (cleaning, routine filling): Generally safe above 30–50 ×10³/μL with local measures; discuss with both dentist and hematologist
• Tooth extraction or oral surgery: Typically requires 50+ ×10³/μL; antifibrinolytic mouth rinse (tranexamic acid) may be used as well
• Regional anesthesia (epidural, spinal): Most anesthesiologists prefer 80+ ×10³/μL; discuss your plan before any scheduled surgery
• Major surgery: Target 50–100 ×10³/μL depending on the procedure; your hematologist will work with the surgical team on a plan
• Childbirth (vaginal or cesarean): Usually safe at 50+ ×10³/μL; epidural anesthesia typically requires 80+; your obstetric team and hematologist should coordinate early in pregnancy
• Neurosurgery or eye surgery (high-risk bleeding): Target often 100+ ×10³/μL

Complete blood count (CBC) with differential: The starting point. Shows the platelet count, red blood cell count, white blood cell count, and details about cell sizes and types. In ITP, the CBC typically shows low platelets but otherwise normal red and white blood cells. Abnormalities in other cell types raise concern for alternative diagnoses (bone marrow disorders, autoimmune diseases affecting multiple blood lines).

Peripheral blood smear: A drop of blood spread on a glass slide and examined under a microscope by a pathologist. This step is critical: it looks at the actual platelets to make sure the low count is real (some automated analyzers falsely undercount platelets in certain conditions, a phenomenon called EDTA-induced pseudothrombocytopenia) and to look for platelet clumping, abnormally large platelets, fragmented red cells, or blast cells that would suggest a different diagnosis.

Reticulocyte count: Measures new red blood cell production. Normal in ITP; elevated in hemolytic anemia (which, combined with low platelets, raises concern for TTP/HUS or Evans syndrome, both of which are medical emergencies requiring different treatment).

Coagulation tests (PT/INR, aPTT): These tests measure the clotting cascade. Normal in ITP. If abnormal, consider a different diagnosis (disseminated intravascular coagulation, antiphospholipid syndrome, liver disease).

Comprehensive metabolic panel: Assesses kidney and liver function. Kidney impairment with low platelets raises concern for TTP/HUS or drug-induced thrombocytopenia. Liver disease can cause low platelets (hypersplenism) and is ruled in or out here.

HIV and hepatitis C testing: Both can cause thrombocytopenia and are among the most common secondary causes of ITP worldwide. Testing is recommended for all new ITP patients.

Antinuclear antibody (ANA): Screens for lupus and related autoimmune diseases, which can cause ITP as a secondary manifestation.

Thyroid function tests (TSH): Thyroid disease (both hypothyroidism and hyperthyroidism, especially Hashimoto's and Graves' disease) is associated with ITP.

H. pylori testing: Urea breath test or stool antigen test. H. pylori eradication can produce platelet responses in up to 60% of H. pylori-positive ITP patients, making it an important and easily treatable secondary cause to identify.

This is one of the most common questions at ITP diagnosis, and the answer has changed over time. Current guidelines (ASH 2019) state that a bone marrow biopsy is not required to diagnose ITP in most patients. A biopsy is generally reserved for:

• Patients over 60 years old (where bone marrow disorders causing low platelets are more common and need to be excluded)
• Patients with unexplained abnormalities in other blood counts (low red cells or white cells that are not explained by the ITP alone)
• Patients who fail to respond to multiple standard treatments as expected, raising doubt about the diagnosis
• Before splenectomy, to ensure there is no bone marrow pathology that would make surgery futile or risky

In a straightforward presentation — a young to middle-aged patient with isolated thrombocytopenia and a normal smear — a bone marrow biopsy adds little information and is not routinely recommended. If your doctor orders one, ask why they believe it is indicated in your specific case.

The most important "look-alikes" that must be considered include:

• Pseudothrombocytopenia: Not a disease — a lab artifact where platelets clump in EDTA (the preservative in blood collection tubes), causing the automated counter to report falsely low counts. Detected on the peripheral blood smear. A repeat count using citrate blood collection typically shows a normal platelet count. This is the first thing to exclude before any ITP workup.
• Thrombotic thrombocytopenic purpura (TTP): A medical emergency requiring urgent plasma exchange. Presents with very low platelets, hemolytic anemia, and organ involvement. Distinguished from ITP by fragmented red cells on smear and elevated LDH. Any hematologist seeing a new low platelet count looks for TTP first because missing it is life-threatening.
• Drug-induced immune thrombocytopenia (DITP): Platelets fall rapidly after starting certain drugs; the platelet count rapidly recovers after the drug is stopped. Important to take a thorough medication history for all prescribed, over-the-counter, and herbal medications. Common culprits: heparin (heparin-induced thrombocytopenia / HIT), quinine, vancomycin, piperacillin-tazobactam, and more recently checkpoint inhibitors (PD-1/PD-L1 inhibitors used in cancer).
• Gestational thrombocytopenia (in pregnant women): Mild thrombocytopenia (platelets 70–150) in pregnancy that resolves after delivery. Distinguished from ITP by mild severity, no prior history of thrombocytopenia, and resolution after birth.
• Bone marrow disorders: Myelodysplastic syndrome (MDS), aplastic anemia, and certain leukemias can cause low platelets by affecting platelet production. Distinguished by abnormalities on peripheral blood smear and bone marrow biopsy when indicated.

A typical, sensible workup includes:

• A complete blood count (CBC) showing isolated low platelets, and a blood smear a specialist looks at under the microscope.
• Tests for treatable secondary causes: HIV and hepatitis C for nearly everyone; testing for H. pylori stomach infection where it is common or if you have symptoms; and, depending on your picture, tests for lupus (ANA), antiphospholipid antibodies, immunoglobulin levels (for immune deficiency), thyroid function, and a pregnancy test.
• A review of your medications and supplements, since some drugs can lower platelets.

A bone marrow biopsy is not routinely required. It is reserved for unusual situations — for example, other abnormal blood counts, features that don't fit, age and risk factors that raise concern for a marrow disorder, or before certain procedures. If your doctor doesn't order one, that is normal and appropriate.

Treatment is generally advised when one or more of the following apply:

• Significant bleeding — more than minor bruising or occasional petechiae (for example, mouth/gum bleeding, frequent nosebleeds, heavy periods, blood in urine or stool, and certainly any internal bleeding).
• A very low count — typically below about 20,000–30,000, where the risk of spontaneous bleeding rises, even without current symptoms (your team will weigh your individual situation).
• An upcoming procedure, surgery, or delivery that needs a higher, safer count.
• Lifestyle or other risks — contact sports, a job with injury risk, a fall risk, or the need to take an anticoagulant or aspirin for another condition.

Even then, the goal is a safe count (enough to prevent bleeding), not a normal one. Chasing a “perfect” number with more and more medication can do more harm than good.

• Have you ruled out platelet clumping (pseudothrombocytopenia) and other causes of low platelets?
• Which secondary causes did you test for, and do I need testing for HIV, hepatitis C, or H. pylori?
• Do I need a bone marrow test — and if not, why not?
• Given my count and symptoms, do I need treatment now, or can I be safely monitored?
• How often will you check my platelets, and what count or symptom would change the plan?
• What number do I need before a dental procedure, surgery, or travel?
• Which of my current medicines or supplements could be making this worse?

High-dose prednisone (1 mg/kg/day for 2–4 weeks, then taper): This is the most common approach. You take the steroid every morning with food. The typical experience:

• Days 1–7: You may feel a surge of energy (even a feeling of being "wired") in the morning after taking the pill. This is from the steroid effect. Sleep may be disrupted — some people find it helpful to take the steroid very early in the morning (6 AM) so the stimulant effect wears off by bedtime.
• Blood sugar: Steroids raise blood sugar, particularly after meals. People with pre-existing diabetes or prediabetes may have significantly elevated sugars and should monitor more closely and contact their primary doctor. Even people without prior diabetes may have high post-meal glucose on high-dose steroids.
• Appetite: Significantly increased appetite is very common. Many people gain weight during prednisone courses. This is a real side effect, not lack of willpower — steroids directly increase appetite signaling.
• Mood changes: Mood lability ("steroid mood"), irritability, anxiety, and in some cases euphoria or depression can occur. These are dose-dependent and improve as the dose is tapered. If mood changes are severe, contact your hematologist.
• The taper: As the platelet count stabilizes, the dose is slowly reduced. The taper is gradual to avoid rebound and to allow the adrenal glands (which are suppressed by steroids) to recover. Don't stop steroids abruptly on your own.

High-dose dexamethasone (40 mg/day for 4 days, repeated in cycles): This regimen produces faster and potentially more durable responses with less cumulative steroid exposure than continuous prednisone. The experience is more concentrated:

• The four days are intense: significant energy, sleep disruption, increased appetite, mood effects
• After the four days stop, these effects resolve quickly — within 1–3 days
• Cycles are repeated (usually 3 monthly cycles) with relative freedom from steroid effects between cycles
• Many patients prefer this regimen for maintaining quality of life between cycles

Sleep: Take the steroid as early in the morning as possible. Melatonin (0.5–3 mg at bedtime) is safe with steroids and can improve sleep onset. Avoid caffeine after noon. If sleep is severely disrupted, contact your doctor about whether a short-term sleep aid is appropriate.

Blood sugar: Eat lower-glycemic meals during steroid treatment (more protein, vegetables, and whole grains; less refined carbohydrates and sugar). Test blood sugar if you are diabetic or have been told you are at risk. Report blood sugars consistently above 200 mg/dL to your doctor.

Bone protection: Long-term steroids reduce bone density. For courses lasting more than a few weeks, doctors typically recommend calcium (1,000–1,200 mg/day from food and supplements) and vitamin D (600–800 IU/day, more if vitamin D levels are low). For chronic or repeated steroid use, bisphosphonate therapy (alendronate or similar) is often recommended to protect bones.

Stomach protection: Steroids increase ulcer risk, particularly if you are also taking NSAIDs (which you shouldn't be in ITP anyway). Taking a proton pump inhibitor (omeprazole, pantoprazole) during high-dose steroid courses is often recommended. Take steroids with food.

Infection risk: Steroids suppress immune function. During high-dose steroid treatment, avoid people with obvious infections. Wash hands frequently. Contact your doctor promptly if you develop fever or signs of infection — they can progress faster than usual when you are immunosuppressed.

Mood: Warn your household members that you may feel more irritable or emotionally variable during steroid treatment. This is expected and temporary. If mood changes feel severe or frightening, contact your doctor immediately — severe psychiatric reactions (steroid psychosis) are rare but real.

• Will I start with prednisone or dexamethasone, and why?
• How long will I be on steroids, and what does the taper schedule look like?
• What platelet count is my treatment goal before we talk about tapering?
• Should I take calcium and vitamin D while on steroids?
• Do I need a stomach protector (proton pump inhibitor) while on steroids?
• What symptoms should make me call you between appointments?
• Are there activity restrictions at my current platelet count?
• What is the plan if steroids don't work or I relapse when we taper?
• Should I be tested for H. pylori?
• When do we consider moving to a second-line treatment?

• Mood, anxiety, irritability, and insomnia — common and temporary. Taking the dose in the morning can help sleep. Tell your team if mood changes are severe.
• Blood sugar — steroids raise it; people with diabetes need closer monitoring, and some people develop temporary high sugars.
• Stomach irritation — your team may add a stomach-protecting medicine and advise taking steroids with food.
• Appetite and weight, fluid retention, and a rounder face are common with longer courses and improve after stopping.
• Bone health and infection risk with longer use — ask about calcium/vitamin D and any vaccines you should have before starting if a long course is planned.
• Never stop a longer steroid course abruptly — it must be tapered. Follow the schedule exactly.

IVIG is given over several hours, sometimes across one or two days. Common, usually manageable side effects include headache (sometimes a delayed, severe headache from aseptic meningitis), fever or chills, nausea, and flushing; slowing the infusion and pre-medication help. Less common but important risks include kidney strain, blood clots, and mild breakdown of red blood cells. Staying well hydrated and telling the nurse about any reaction during the infusion are key.

• Which steroid will I take, at what dose, and for exactly how long (including the taper)?
• What is your plan to limit my total steroid exposure?
• What side effects should I expect, and what can we do to reduce them (sleep, blood sugar, stomach, bones)?
• Will I need IVIG — and if so, is it for bleeding, a procedure, or to bridge to another medicine?
• Am I a candidate for anti-D, or is IVIG better for me?
• What is the plan if I relapse when the steroids stop?
• What is my target count, and when will we re-check it?

Thrombopoietin receptor agonists (TPO-RAs) work by stimulating the bone marrow to produce more platelets faster than the immune system can destroy them. They don't suppress the immune system — they simply increase production. This is a fundamentally different approach from steroids.

Eltrombopag (Promacta): A once-daily pill taken on an empty stomach (no food for 4 hours before and 2 hours after). Platelet counts typically rise within 1–2 weeks. Benefits:

• No immune suppression — no increased infection risk from the drug itself
• Convenient daily oral dosing
• Very high response rate (70–80% of patients achieve counts >50)
• Can be used indefinitely as a maintenance treatment

Considerations: Must be taken away from food and calcium-containing foods (including dairy). Liver function tests must be monitored regularly. Bone marrow fibrosis (scarring) is a theoretical long-term concern (a mandatory rest period is built into prescribing labels for this reason). Cost is significant; patient assistance programs are available through the manufacturer (Novartis).

Romiplostim (Nplate): A weekly subcutaneous injection given at home or in a clinic. Works the same way as eltrombopag. Benefits:

• No food restrictions — injectable route bypasses GI absorption issues
• Weekly dosing rather than daily (some patients prefer a weekly rather than daily medication burden)
• Very high response rate comparable to eltrombopag

Considerations: Requires subcutaneous injection (training provided; most patients become comfortable with self-injection). Weekly clinic visits required if not self-injecting. Similar bone marrow monitoring considerations as eltrombopag. High cost; patient assistance available through Amgen.

Compared to each other: Response rates and safety profiles are similar between eltrombopag and romiplostim. The choice is often personal preference (pill vs. injection, daily vs. weekly, food restrictions vs. not).

Fostamatinib (Tavalisse) works by blocking a signaling enzyme (SYK) involved in the destruction of antibody-coated platelets. It's an oral pill taken twice daily with food.

• Response rate roughly 40–50% — lower than TPO-RAs, but works through a completely different mechanism
• Particularly useful in patients who have failed TPO-RAs, because it may work when they didn't
• Common side effects: diarrhea (often improves over weeks), high blood pressure (monitor BP), nausea, liver enzyme elevation. Managing hypertension may require addition of an antihypertensive medication.
• Requires blood pressure monitoring and liver function monitoring during treatment

Rituximab is an intravenous infusion drug originally developed for certain blood cancers that depletes B cells — the cells that produce the antibodies attacking your platelets. In ITP, it is given as 4 weekly infusions (or sometimes as 2 infusions depending on the protocol).

• Overall response rate: 40–60% at 6 months
• Important distinction from TPO-RAs: Rituximab can produce a true remission — a period where ITP is in remission without ongoing medication. About 20–25% of rituximab responders maintain response at 2 years. TPO-RAs generally require ongoing treatment to maintain response.
• The trade-off: lower and less predictable response rate than TPO-RAs, but the possibility of medication-free remission makes it an attractive option, especially for younger patients who want to avoid indefinite daily medication
• Infusion reactions are possible during the drip (managed at the infusion center); serious infections are the main long-term concern given B cell depletion lasting up to 6–12 months
• Vaccines: update all vaccines at least 4 weeks before rituximab if possible; avoid live vaccines for at least 6 months after
• Can be repeated if ITP relapses after an initial response

The spleen is the primary site where antibody-coated platelets are destroyed in ITP, and it also produces many of the antibodies attacking platelets. Surgical removal of the spleen (splenectomy) eliminates both the destruction site and an antibody factory. It is the oldest effective treatment for ITP and still produces the most durable remissions of any treatment.

• Remission rate: Approximately 60–80% of patients who have splenectomy achieve a complete response (platelet count normalizes). About two-thirds of responders maintain that response long-term (5+ years).
• Why doctors now wait: Guidelines generally recommend waiting at least 12–24 months before considering splenectomy, because some ITP resolves on its own in the first 1–2 years. Surgery carries risks that are worth avoiding if remission might occur spontaneously.
• The surgery: Splenectomy is now most commonly done laparoscopically (small incisions, video-guided). Recovery time is typically 2–4 weeks for laparoscopic surgery, much faster than the older open surgery.
• Long-term implications: Living without a spleen increases risk of certain serious bacterial infections (pneumococcal, meningococcal, Haemophilus influenzae). Before splenectomy, you must receive vaccinations against these bacteria. After splenectomy, many centers recommend daily penicillin prophylaxis for 2 years, and some recommend it lifelong. You should carry a card indicating you are asplenic and seek medical care early with any fever — infections can progress rapidly without a spleen.
• Questions to ask your surgeon before splenectomy: Will this be laparoscopic? What vaccinations do I need first? Will I need lifelong penicillin? What is the hospital's experience with ITP splenectomy? What happens if splenectomy doesn't work?

• Blood counts are checked regularly, especially when starting or changing the dose, to find the lowest dose that keeps you safe. The aim is usually a count above 50,000–but-not-too-high, not a maxed-out number.
• Clot risk. Because these raise platelets, there is a small increased risk of blood clots, especially if you have other clot risk factors. Report leg swelling/pain, chest pain, or shortness of breath.
• Eltrombopag needs periodic liver tests and the food/mineral spacing above; people of East Asian ancestry often need a lower starting dose.
• Bone marrow. Long-term TPO-RAs can cause a usually-mild, reversible increase in marrow fibers (reticulin); this is monitored and rarely a problem.
• Don't stop suddenly without a plan — counts can drop (sometimes below where they started) after stopping. Tapering is done deliberately.

There is no single “correct” order that fits everyone, and guidelines deliberately leave room for choice. A common pattern looks like this:

1. First-line: a short steroid course (with IVIG/anti-D if a fast rise is needed).
2. Second-line (ongoing): usually a TPO-RA (romiplostim, eltrombopag, or avatrombopag), or fostamatinib, or rituximab — chosen with you based on how they fit your life and health. Rilzabrutinib adds another oral option here for persistent/chronic disease.
3. If several therapies don't hold: switching between TPO-RAs, combining mechanisms, considering splenectomy, and exploring newer agents or a clinical trial.

Your preferences matter a great deal here: pill vs. injection vs. infusion, daily vs. weekly vs. a one-time course, monitoring needs, and the chance of one day stopping treatment are all fair to weigh.

• Among the TPO-RAs, which fits my life best — a weekly injection or a daily pill — and why?
• If I start a TPO-RA, what monitoring do I need, and could I eventually taper off?
• Is fostamatinib a good option for me, and what blood-pressure/liver monitoring does it need?
• Would rituximab make sense given my situation, and how long might it last?
• Is rilzabrutinib an option for me, and how does it compare to the others?
• Is splenectomy something we should consider — and if so, which vaccines do I need first and what are the lifelong precautions?
• If one treatment doesn't work, what's next — switching, combining, or a trial?
• Which option gives me the best chance of being treatment-free someday?

Petechiae: Small (pinpoint) red or purple spots on the skin, especially on legs and ankles, that do not blanch when pressed. These are tiny hemorrhages from capillaries under the skin. They look alarming but are generally not dangerous. They indicate a low platelet count. They typically fade over days as the blood is reabsorbed.

Purpura: Larger flat purple or red patches on the skin, also from bleeding under the skin. Easily confused with bruises but form without injury. Again, concerning cosmetically and a sign of low counts, but not dangerous by themselves.

Bruising: Deep bruising, especially on extremities, without significant injury is common with counts below 50. These are uncomfortable and discoloring but not dangerous.

Wet purpura (blood blisters in the mouth): Blood-filled blisters on the inside of the mouth or tongue are a more serious sign that correlates with very low platelet counts (often below 10). If you see these, contact your hematologist the same day.

Nosebleeds: Common in ITP, especially with counts below 30. Most nosebleeds can be managed at home (lean forward slightly, pinch soft part of nose for 10–15 minutes). If a nosebleed does not stop after 30 minutes of sustained direct pressure, go to an emergency room.

Heavy menstrual bleeding: Women with ITP often experience heavier and longer periods with low platelet counts. A period requiring more than one pad or tampon per hour for several hours is abnormal and should be reported to your hematologist for management. Iron deficiency from chronic menstrual blood loss should be assessed regularly.

These symptoms require emergency evaluation regardless of what your most recent platelet count was:

• Sudden, severe headache — the most important symptom to know. Intracranial hemorrhage (bleeding in the brain) is the most serious complication of ITP. It is rare but can present as a sudden, severe headache unlike any experienced before. Do not wait — call 911 or go immediately to the ER.
• Vision changes (sudden blurring, loss of vision in one eye, or seeing flashing lights or shadows)
• Slurred speech, weakness on one side, confusion — these are stroke symptoms, which can occur with intracranial hemorrhage
• Coughing or vomiting blood (not streaks — significant amounts)
• Blood in urine that turns the toilet red or brown (not just pink tinge)
• Black or tarry stools (which indicate upper GI bleeding)
• Nosebleed not stopped after 30 minutes of direct pressure
• Head injury of any significance — even if you feel fine, intracranial bleeding from a head injury in ITP can develop over hours

• Petechiae — pinpoint red or purple dots, often on the lower legs, that don't fade when pressed. A classic sign of low platelets.
• Lots of new bruising (purpura) — especially large or in unusual places, or appearing without injury.
• Nosebleeds or gum bleeding that are frequent or hard to stop.
• Blood blisters in the mouth (“wet purpura”) — bleeding inside the mouth can be a sign of a higher bleeding risk; report it promptly.
• Blood in the urine (pink/red) or stool (red or black/tarry).
• Unusually heavy or prolonged menstrual periods.
• The brain red flags above — severe headache, confusion, vision change, weakness — which are emergencies.

• At my current count, what is my realistic bleeding risk?
• Which symptoms mean “call the clinic” and which mean “go to the ER”?
• What is the after-hours number, and what should I tell the ER about my ITP?
• Which pain relievers are safe for me, and which must I avoid?
• I take a blood thinner / aspirin — how should we manage that with my ITP?
• Should I carry a medical alert card or wear a bracelet?
• What is the emergency plan if I have serious bleeding or a head injury?

Fatigue is one of the most under-discussed symptoms in ITP. It is not always caused by low platelets directly — in fact, people with very similar platelet counts can have completely different fatigue levels. The causes of fatigue in ITP include:

• The underlying immune dysregulation itself: Chronic immune activation is metabolically demanding and can cause fatigue independent of platelet count
• Corticosteroid use: Long-term or repeated steroid courses cause muscle weakness, mood changes, and disrupted sleep — all contributing to fatigue
• Anxiety and hypervigilance about symptoms: Chronic monitoring of bruises, checking for petechiae, and the general psychological burden of ITP causes mental fatigue
• Blood loss: In women with heavy menstrual bleeding from ITP, iron deficiency develops and significantly worsens fatigue. Iron supplementation in this group specifically produces real improvement.
• Sleep disruption: ITP-related anxiety commonly disrupts sleep, which amplifies all other fatigue

What helps with ITP fatigue:

• Addressing treatable contributors: iron deficiency testing and treatment, medication side effect review with your hematologist
• Pacing: planning high-energy activities for your best time of day, not fighting through fatigue without rest
• Gentle exercise: paradoxically, light regular exercise (walking, swimming) improves energy levels in chronic conditions, even when it feels counter-intuitive. Discuss with your hematologist which activities are safe at your platelet level.
• Sleep hygiene and addressing anxiety (see mental health section below)

Studies consistently show that people with ITP have significantly higher rates of anxiety and depression than the general population, even in people whose platelet counts are in a "safe" range. The sources of psychological distress in ITP include:

• Unpredictability: The fluctuating platelet count makes it difficult to plan life. Will I be well enough for the family trip? Should I book the hiking vacation?
• Invisibility: ITP is largely invisible. People look normal on the outside. This can make it hard for others to understand the seriousness of the condition, which is isolating.
• Fear of bleeding: Even when counts are not critically low, the knowledge that a count could drop creates background anxiety. Any new bruise or headache triggers alarm.
• Treatment burden: Frequent blood draws, doctor visits, medication costs, and the side effects of treatments (especially steroids) add daily life burden.
• Uncertainty: Will this go away on its own? Will I need to be on medication forever? What happens when I want surgery?

Effective help is available:

• Acknowledge the psychological impact to your hematology team. Many centers have integrated psycho-oncology or hematology psychology services. Ask for a referral.
• Cognitive behavioral therapy (CBT) adapted for health anxiety has strong evidence for reducing chronic disease anxiety. Several validated programs are available via telehealth, making them accessible without travel.
• PDSA (Platelet Disorder Support Association) at pdsa.org offers peer counselor matches, online support groups, and mental health resources specifically for ITP patients.
• Medication: If anxiety or depression is significant, antidepressants and anxiolytics are not contraindicated in ITP (discuss with your doctor which options are safest at your platelet level).

Activity restriction is one of the most quality-of-life-impacting aspects of ITP, particularly for children and young adults. The goal is not to stop all activity — it is to match activity level to bleeding risk, which is primarily determined by platelet count and the specific activity.

General activity guidance by platelet count range (always discuss with your hematologist):

• Above 50 ×10³/μL: Most non-contact activities are generally safe: walking, jogging, cycling on flat terrain, swimming, yoga, golf, tennis (non-competitive). Avoid activities with high head-injury risk (boxing, contact martial arts, tackle football, ice hockey).
• 30–50 ×10³/μL: Light-to-moderate exercise generally continues to be safe. Contact sports are more cautiously avoided. Wear helmets for cycling; avoid motorcycles. Discuss skiing and other fall-risk activities with your hematologist.
• Below 30 ×10³/μL: Significant restriction is usually recommended. Walking, gentle swimming, and non-impact activities may continue. Avoid activities with any significant fall, impact, or collision risk. No heavy lifting that causes significant Valsalva straining. Exercise bikes and gentle stretching are generally acceptable.
• Below 10 ×10³/μL: Bed rest is not necessary but strenuous activity should be restricted. Quiet daily activities are generally acceptable; avoid all impact activities.

Protective equipment: For people who continue to cycle, skate, or do outdoor activities, helmet use is non-negotiable in ITP. Consider wrist guards and knee pads for higher-risk activities even at higher platelet counts. Medical ID bracelets identifying you as an ITP patient are advisable for those who engage in any significant physical activity.

No specific diet is proven to raise platelet counts or cure ITP. However, several dietary factors affect bleeding risk and treatment response:

• Alcohol: Alcohol has a direct toxic effect on platelet production at moderate-to-high intake levels. Even one to two drinks can temporarily impair platelet function (how well existing platelets work) independently of the count. People with ITP should minimize alcohol. Heavy drinking can directly suppress bone marrow platelet production.
• Fish oil / omega-3 supplements at high doses: High-dose fish oil (more than 2–3 grams/day of EPA+DHA) impairs platelet aggregation and should be avoided or used very cautiously in ITP. Standard dietary levels from eating fish are generally safe.
• Vitamin E at high doses: Similar to fish oil, high-dose vitamin E (>400 IU/day) impairs platelet function. Standard multivitamin doses are fine.
• Aspirin and NSAIDs (ibuprofen, naproxen): These inhibit platelet function and should generally be avoided in ITP. For pain, acetaminophen (Tylenol) is safe at standard doses. Discuss all over-the-counter medications with your hematologist or pharmacist.
• Quercetin, papaya leaf extract, and other "natural" platelet boosters: None of these have been proven to raise platelet counts in ITP in controlled trials. They do not replace medical treatment. Some supplements interact with ITP medications — always disclose all supplements to your hematologist.
• Iron: For women with heavy menstrual bleeding from ITP, iron deficiency is common and should be treated. Iron supplementation does not raise platelets but significantly improves energy levels and quality of life in people who are deficient.

For most people with ITP, pregnancy is safe. The fundamental biology: ITP does not damage fertility, does not cause miscarriage, and does not cause major structural birth defects. The main considerations are:

• Your platelet count will often fluctuate during pregnancy. Many people with ITP find their platelet count drops during the first trimester (due to increased blood volume and immune changes), may stabilize in the second trimester, and can drop again near delivery. Your hematologist will increase monitoring frequency during pregnancy, often monthly or more frequently.
• Some ITP medications are not safe in pregnancy. TPO receptor agonists (eltrombopag, romiplostim), fostamatinib, and rituximab are generally avoided in pregnancy due to insufficient safety data or known concerns. If you are on these medications and planning pregnancy, discuss a transition plan with your hematologist well before you attempt to conceive — medication changes take time to implement safely.
• Safe treatments during pregnancy: Prednisone/prednisolone and IVIg are the primary treatments used. Prednisone crosses the placenta minimally (the fetal liver converts it to an inactive form). IVIg is safe and can be used on an as-needed basis to boost counts before delivery. Anti-D immunoglobulin is also safe in Rh-positive pregnant women.
• The baby's platelets may be affected. The antibodies that destroy your platelets can cross the placenta and affect fetal/neonatal platelets. This is usually mild and self-resolving after birth as your antibodies clear from the baby's circulation. Severe fetal thrombocytopenia (which could affect delivery choices) is uncommon.

Before conception:

• Discuss your ITP status with your hematologist at least 3–6 months before trying to conceive
• If you are on a TPO-RA or fostamatinib, plan the transition off these medications and to a pregnancy-safe alternative. Allow adequate time to confirm platelet count remains stable off the medication before conceiving.
• Get your platelet count into the most stable range possible before conception
• Identify or confirm your OB/GYN and whether they have experience with ITP, or whether referral to a maternal-fetal medicine specialist is appropriate. MFM referral is appropriate for any woman with ITP and a history of platelet counts below 50, or who has required ongoing treatment for ITP.

During pregnancy — monitoring schedule:

• First trimester: CBC monthly (more frequently if counts are below 50 or dropping)
• Second trimester: CBC monthly
• Third trimester: CBC every 2–4 weeks
• Last 4–6 weeks: CBC every 1–2 weeks; pre-delivery platelet count assessment needed

For delivery:

• Target platelet count for vaginal delivery: >50 ×10³/μL
• Target for epidural anesthesia: >80 ×10³/μL (most anesthesiologists require this)
• If count is below target near delivery: IVIg (1 g/kg) given 1–2 weeks before delivery can reliably boost counts for 2–4 weeks; prednisone may also be used
• Notify the delivery hospital in advance that you have ITP and work with your team to create a written delivery plan that all providers (including anesthesia and NICU) can access

A cord blood platelet count is obtained at birth in newborns of mothers with ITP. If the baby's count is normal or mildly reduced (>50), monitoring is typically all that is needed. If severely low (<20–30), IVIg for the baby may be given.

Important to know: the nadir of neonatal thrombocytopenia from passively acquired maternal antibodies typically occurs at day 2–7 after birth, not at birth itself. CBC checks in the first week of life are important. The baby's platelet count will recover completely within a few weeks as your antibodies clear from their circulation. This is different from neonatal alloimmune thrombocytopenia (NAIT, a different condition) where the risk is more severe and more complex.

• Delivery count targets. Your team will aim for a platelet count high enough for a safe delivery and, if you want an epidural/spinal, high enough for anesthesia — often a somewhat higher target for neuraxial anesthesia. These targets are individualized.
• The baby's platelets. The antibodies can cross the placenta, so a minority of babies are born with low platelets. This is checked with cord/newborn blood, and the lowest count often occurs a few days after birth, so the baby is monitored. Importantly, the mother's count does not reliably predict the baby's; a history of a previously affected baby is the strongest clue.
• Mode of delivery is usually decided by obstetric reasons, not ITP alone.

• Is my low count ITP or gestational thrombocytopenia, and how can you tell?
• Will I need treatment during pregnancy, and which medicines are safe for me?
• What platelet count are we aiming for at delivery, and can I have an epidural?
• How and when will my baby's platelets be checked after birth?
• What activities should I avoid at my current count, and which are fine?
• Are my vaccines up to date, and are any especially important for me?
• I've been very tired — could that be related to ITP, and what can help?

Every person with ITP should have a written emergency summary they carry and share with their household. This should include:

• Current platelet count range (your typical stable count, your last measured count, and date)
• Current ITP medications and doses including exact drug names, doses, and prescriber name/phone
• Your hematologist's name, clinic phone, and after-hours contact
• Medications you cannot receive: List aspirin, NSAIDs, clopidogrel/antiplatelet drugs, and any other platelet-inhibiting drugs. If you have had an adverse reaction to any ITP treatment, include that.
• Emergency treatment notes: For patients on IVIg or who have had rescue treatment, note what worked and at what dose. This saves crucial time in an emergency.
• Blood type if known

When to go to the emergency room: Go immediately if you have:

• Headache that is sudden, severe, or different from any headache you have had before (intracranial bleeding can present this way)
• Vision changes (sudden blurring, double vision, or loss of visual field)
• Bleeding that you cannot stop with direct pressure after 10–15 minutes
• Significant trauma (fall, car accident, head impact) even if you feel okay
• Coughing or vomiting blood, or blood in your urine or stool in significant amount
• Extreme weakness or confusion

ITP does not need to stop travel. With preparation, most people with stable ITP can travel domestically and internationally without special arrangements. People with active or unstable ITP should discuss upcoming travel with their hematologist in advance.

Before any significant trip:

• Get a recent platelet count (within 2–4 weeks) and confirm with your hematologist that your count is stable enough for the trip
• Carry your written ITP summary (see above) in both English and the local language for international trips
• Pack enough medication for the full trip plus at least one week extra; carry medications in your carry-on, not checked luggage
• Ask your hematologist for a brief letter summarizing your diagnosis, current treatment, and any medications that must be avoided. This is invaluable if you need care abroad.
• Locate the nearest hospital/hematology service at your destination before you leave. Most large cities internationally have hematology services.
• For long international trips, consider contacting the U.S. Embassy or Consulate of your destination to understand local healthcare systems and whether your travel insurance covers ITP-related care.

Travel insurance: Standard travel insurance often excludes pre-existing conditions including ITP. Look specifically for travel insurance that covers pre-existing conditions (usually requires purchase within 2 weeks of your first trip payment). Companies like Allianz, Travel Guard, and some specialty medical travel insurers offer this coverage. The additional cost is modest compared to an international hospitalization without coverage.

Air travel: Flying is safe with ITP at most platelet counts. Note that airplane cabins are dry, which can worsen nosebleeds in some people with ITP; nasal saline spray can help. Stay hydrated during flights. Wear compression stockings if platelet count is above 50 to prevent DVT during long flights (paradoxically, while ITP causes bleeding risk, the risk of clotting from immobility still exists, especially in people on TPO-RAs).

• Rilzabrutinib (BTK inhibitor) — LUNA 3 (NCT04562766): the pivotal phase 3 study (adults and adolescents) that supported the 2025 FDA approval of Wayrilz for persistent/chronic ITP.
• Efgartigimod (FcRn antagonist) — ADVANCE / ADVANCE‑IV (NCT04188379) and its long-term extension ADVANCE+ (NCT04225156): the studies behind efgartigimod's ITP approval in Japan.
• Efgartigimod — advance NEXT (NCT06544499): an active, recruiting global confirmatory phase 3 study of IV efgartigimod in chronic primary ITP (supporting potential approval beyond Japan).
• Fostamatinib — FIT1 (NCT02076399) and FIT2 (NCT02076412): the phase 3 trials supporting its approval.
• TPO receptor agonists: romiplostim (NCT00102323, NCT00102336), eltrombopag — RAISE (NCT00370331), and avatrombopag (NCT01438840) — the registration trials for the platelet-boosters.

How to search: go to ClinicalTrials.gov and search “immune thrombocytopenia” plus your city/region, or a specific drug name. Filter by “Recruiting.” The Platelet Disorder Support Association (PDSA, pdsa.org) also maintains plain-language trial information and a community that shares experiences. Always discuss any trial with your own hematologist.

• Long-term steroids as a maintenance strategy. Once common, now discouraged — the side-effect burden outweighs the benefit when better-tolerated options exist.
• Routine, early splenectomy. Still effective, but no longer a default early step; it's delayed and used selectively now that many medicines are available.
• Older broad immunosuppressants (such as azathioprine, cyclophosphamide, cyclosporine, danazol, vinca alkaloids) are now largely reserved for refractory disease or specific situations, having been displaced by TPO-RAs, fostamatinib, and newer agents that are more effective and better studied.
• Supplements and “immune-boosting” herbal regimens marketed for ITP are not proven to raise platelets and are not a substitute for standard care. Some carry real risks: certain herbal products and high-dose supplements can increase bleeding or interact with your medicines. Always tell your team about anything you take, and don't replace effective treatment with unproven remedies.
• “Just raise the number at all costs” is itself a de-adopted idea — over-treating to chase a normal count causes harm. The modern goal is a safe count with the least treatment necessary.

• University of Utah Health / Huntsman Cancer Institute — Hematology (Salt Lake City). Comprehensive ITP diagnosis and management: steroids, IVIG, TPO-RAs, fostamatinib, rituximab, splenectomy evaluation, refractory and secondary disease, and clinical trials. Main: 801-587-7000; cancer patient line 1-888-424-2100.
• Intermountain Health — Hematology Clinics & Infusion Centers (Murray and across the Wasatch Front/Utah). ITP care, IVIG and rituximab infusions, and platelet monitoring. Intermountain Medical Center main: 801-507-7000.
• Primary Children's Hospital — Pediatric Hematology (Salt Lake City). Evaluation and management of childhood ITP (often self-limited). Main: 801-662-1000.
• Specialty pharmacies & infusion centers (University of Utah, Intermountain). Administer IVIG and infused therapies, teach romiplostim self-injection, and coordinate specialty-drug prior authorizations and patient-assistance programs.

• Massachusetts General Hospital — Hematology (Boston). Major ITP research and care center. Main: 617-726-2000.
• Weill Cornell Medicine / NewYork-Presbyterian (New York). Longstanding ITP expertise. Main: 212-746-5454.
• Johns Hopkins — Hematology (Baltimore). Main: 410-955-5000.
• Mayo Clinic — Hematology (Rochester, MN). Main: 507-284-2511.
• Cleveland Clinic — Hematology & Medical Oncology (Cleveland). Main: 216-444-2200.

• George E. Wahlen VA Medical Center — Hematology (Salt Lake City). ITP care for veterans. Main: 801-582-1565 / 1-800-613-4012.
• Most VA medical centers have hematology services; if ITP care or a needed medication isn't available locally, ask about community care referral and whether your thrombocytopenia is service-connected, which can affect coverage.

• McMaster University / Hamilton Health Sciences — Hematology (Hamilton, ON). Internationally recognized ITP research and care.
• University Health Network / University of Toronto — Hematology (Toronto, ON).
• Coverage note: TPO-RAs and newer agents are generally accessed through provincial drug programs and private insurance, often with eligibility criteria (e.g., prior therapies tried). A hematology clinic's pharmacy navigator can help with applications; steroids and IVIG are widely available.

• United Kingdom: Imperial College Healthcare / Hammersmith and Guy's & St Thomas' (London) — major ITP centers; care follows British Society for Haematology guidance, with TPO-RAs and newer agents accessed via NHS/NICE pathways.
• France: the national reference network for adult immune cytopenias (centres de référence, including Hôpital Henri-Mondor, Créteil) coordinates expert ITP care.
• Germany, Italy, Spain, Japan, China, Korea, Australia: national hematology societies maintain ITP guidelines and expert centers; access to TPO-RAs and newer agents varies by health system (see the International section).

• Steroids and IVIG — available essentially everywhere; the global mainstay.
• TPO-RAs (romiplostim, eltrombopag, avatrombopag) — approved across the US (FDA), Europe (EMA), Japan (PMDA), Canada, UK, and many other regions, but reimbursement/access criteria differ. Avatrombopag's approvals are somewhat more recent and uneven than the older two.
• Fostamatinib — approved in the US and Europe for chronic ITP; access elsewhere varies.
• Rituximab — widely available (used off-label for ITP in most countries); biosimilars improve access.
• Rilzabrutinib (Wayrilz) — FDA-approved (Aug 2025) and approved in the United Arab Emirates; under review in the EU and other regions.
• Efgartigimod (Vyvgart) for ITP — approved for ITP in Japan (2024); not yet FDA- or EMA-approved for ITP (confirmatory trials ongoing). It is approved in the US/EU for other antibody-driven diseases.
• Secondary causes vary by region: where hepatitis C, HIV, or H. pylori are common, treating those infections is an especially important part of ITP care.

• Platelet: the small blood cell fragment that helps you stop bleeding.
• Thrombocytopenia: a low platelet count.
• Petechiae: pinpoint red/purple skin dots from tiny bleeds.
• Purpura: larger purple bruise-like patches of bleeding under the skin.
• Pseudothrombocytopenia: a falsely low count from platelet clumping in the lab tube — not real ITP.
• Primary vs. secondary ITP: standalone vs. linked to another condition.
• Newly diagnosed / persistent / chronic: ITP within 3 months / 3–12 months / beyond 12 months.
• Corticosteroid (steroid): a medicine (prednisone, dexamethasone) that calms the immune system.
• IVIG: intravenous immunoglobulin — a donor-antibody infusion that quickly but temporarily raises platelets.
• Anti-D: a fast-acting option for Rh-positive people who still have a spleen.
• TPO-RA (thrombopoietin receptor agonist): a platelet-booster (romiplostim, eltrombopag, avatrombopag) that tells the marrow to make more platelets.
• Fostamatinib: an oral SYK inhibitor that reduces immune destruction of platelets.
• Rituximab: an infusion that lowers antibody-making B-cells.
• Splenectomy: surgical removal of the spleen (a main site of platelet destruction).
• BTK inhibitor (rilzabrutinib): an oral medicine that calms the immune attack through the BTK pathway.
• FcRn antagonist (efgartigimod): a medicine that lowers harmful antibodies by blocking their recycling.
• Refractory: ITP that hasn't responded to multiple treatments.
• Remission: a safe platelet count, sometimes lasting after treatment stops (treatment-free remission).

• ASH 2019 ITP Guidelines — Neunert C, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances 2019;3(23):3829–3866.
• International Consensus Report (ICR) 2019 — Provan D, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Advances 2019;3(22):3780–3817.
• Terminology/outcomes — Rodeghiero F, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura. Blood 2009;113(11):2386–2393.
• Rilzabrutinib — LUNA 3 phase 3 (NCT04562766); FDA approval of Wayrilz for persistent/chronic ITP, August 2025.
• Efgartigimod — ADVANCE (NCT04188379) and ADVANCE+ (NCT04225156); Japan (PMDA/MHLW) ITP approval, 2024; advance NEXT confirmatory study (NCT06544499).
• Fostamatinib — FIT1/FIT2 (NCT02076399, NCT02076412); FDA label (Tavalisse).
• TPO-RAs — romiplostim (NCT00102323, NCT00102336; Nplate label), eltrombopag RAISE (NCT00370331; Promacta/Revolade label), avatrombopag (NCT01438840; Doptelet label).
• Patient organization — Platelet Disorder Support Association (PDSA), pdsa.org; American Society of Hematology patient resources; ClinicalTrials.gov.

Watch for bleeding warning signs. New or widespread bruising, petechiae (tiny red skin dots), nosebleeds or gum bleeding that won't stop, blood in urine or stool, and unusually heavy periods all warrant a call and a platelet check. Treat a severe headache, confusion, vision change, weakness, slurred speech, or seizure as a 911 emergency — these can signal bleeding in the brain. Call the team after any head injury, even a minor one.

Help avoid bleeding-risk medicines. Keep aspirin, ibuprofen, naproxen, and other NSAIDs out of the routine unless approved — including hidden NSAIDs in combination cold/pain products. Keep a current medication and supplement list to show clinicians.

Support steroid routines. Help with timing (morning dosing for better sleep), taking pills with food and any stomach protection, watching for big mood/sleep/blood-sugar changes, and never stopping a longer course abruptly — follow the taper.

Keep monitoring on track. Platelet appointments are the backbone of safe ITP care; help schedule and attend them, and keep the simple log (counts, symptoms, new meds).

Help with the specific treatment. Learn romiplostim self-injection technique together; build the eltrombopag empty-stomach/no-minerals routine; keep avatrombopag “with food” consistent; help track infusion appointments for IVIG/rituximab.

If the spleen is removed, support the vaccination schedule beforehand and the lifelong precautions afterward: prompt medical care and antibiotics for fevers, a medical alert card, and staying current on vaccines.

Provide emotional support. ITP fluctuates unpredictably; patience, steady presence, and encouraging connection with peer communities make a real difference.

• Is a clinical trial an option for me now or in the future?
• Should I be seen at a specialized ITP/hematology center?
• Are there patient-assistance programs to help with the cost of my medicines?
• Can you connect me with peer support (such as PDSA)?
• What should my caregiver know about emergencies and my medicines?
• Is any treatment I'm using approved and covered where I live, and what are the alternatives if not?